CRISPR, (Clustered Regularly Interspaced Short Palindromic Repeats), is a technology that allows scientists to edit genes in living cells.
Bloomberg Markets with Carol Massar and Jason Kelly. Mitchell Ng, Managing Director at Thessalus Capital, is a 23-year old medical student who also invests in biotech. He discusses why he likes TG Therapeutics, aming others.
It holds vast applications, from curing genetic diseases, detecting and treating cancers, treating HIV by blocking replication in human cells, bioengineering new crops and plants, eliminating malaria, to editing DNA in live human embryos.
Starting a hedge fund and making millions remains one of the most glamorized paths to fame and fortune in America. It's the tried and true storyline in Hollywood hits from Wolf of Wall Street and The Big Short.
Investing in healthcare poses a unique challenge. Healthcare is enormously complex, only rewarding fund managers with deep technical understanding of scientific and regulatory developments within the industry.
Thessalus Capital Management, a student-run investment fund based in Princeton, NJ, beat the odds in 2015. In a year of flatline markets, with the S&P 500 returning 1.4% and the average Wall Street hedge fund posting -3%, Thessalus notched a +7% gain after incorporation in September.
Source: Yahoo Finance